Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Equillium Inc (EQ)

7.19   -0.01 (-0.14%) 03-03 16:59
Open: 7.44 Pre. Close: 7.2
High: 7.68 Low: 7.15
Volume: 211,873 Market Cap: 209M
Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 16 full-time employees. The firm develops products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its initial product candidate, EQ001 (itolizumab), is a clinical-stage, monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the modulation of effector T cells, or Teff cells. Activated Teff cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. EQ001, disease modifying treatment for multiple severe immuno-inflammatory disorders. The company plans to initiate a Phase Ib/II clinical trial of EQ001 for the treatment of acute graft-versus-host disease, or aGVHD.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.755 - 7.799 7.799 - 7.847
Low: 7.033 - 7.079 7.079 - 7.129
Close: 7.103 - 7.183 7.183 - 7.27

Technical analysis

as of: 2021-03-03 4:39:31 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 10.68     One year: 13.23
Support: Support1: 5.61    Support2: 4.67
Resistance: Resistance1: 9.14    Resistance2: 11.33
Pivot: 8.67
Moving Average: MA(5): 7.30     MA(20): 8.55
MA(100): 5.93     MA(250): 5.51
MACD: MACD(12,26): 0.16     Signal(9): 0.52
Stochastic oscillator: %K(14,3): 8.11     %D(3): 7.84
RSI: RSI(14): 44.80
52-week: High: 27.05  Low: 2.20  Change(%): 50.1
Average Vol(K): 3-Month: 74843  10-Days: 34857

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
EQ has closed above bottom band by 18.4%. Bollinger Bands are 116.4% wider than normal. The large width of the bands suggest high volatility as compared to EQ's normal range. The bands have been in this wide range for 18 bars. This is a sign that the current trend might continue.

Headline News

Wed, 03 Mar 2021
Equillium (NASDAQ:EQ) Earns Buy Rating from Analysts at Jonestrading - MarketBeat

Tue, 02 Mar 2021
Equillium to Present at the H.C. Wainwright Global Life Sciences Conference - GlobeNewswire

Thu, 18 Feb 2021
Equillium to Present at the SVB Leerink 10th Annual Global Healthcare Conference - Yahoo Finance

Fri, 12 Feb 2021
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience - Yahoo Finance

Tue, 09 Feb 2021
Equillium (EQ) Receives a Rating Update from a Top Analyst - Analyst Ratings

Tue, 09 Feb 2021
Equillium Announces the Appointment of Katherine Xu to the Board of Directors - GlobeNewswire

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 25
Shares Float (M) 14
% Held by Insiders 44.12
% Held by Institutions 34.21
Shares Short (K) 752
Shares Short P. Month (K) 375

Stock Financials

EPS -1.540
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 3.160
Profit Margin
Operating Margin
Return on Assets (ttm) -22.7
Return on Equity (ttm) -44.8
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -1.139
Qtrly Earnings Growth
Operating Cash Flow (M) -25
Levered Free Cash Flow (M) -16

Stock Valuations

PE Ratio -4.67
PEG Ratio
Price to Book value 2.28
Price to Sales
Price to Cash Flow -7.00

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.